Synonym
CCT020312; CCT-020312; CCT 020312.
IUPAC/Chemical Name
6-Bromo-3-[5-(4-bromo-phenyl)-1-(3-diethylamino-propionyl)-4,5-dihydro-1H-pyrazol-3-yl]-4-phenyl-1H-quinolin-2-one
InChi Key
OAXDKXMGESZLKV-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H30Br2N4O2/c1-3-36(4-2)17-16-28(38)37-27(20-10-12-22(32)13-11-20)19-26(35-37)30-29(21-8-6-5-7-9-21)24-18-23(33)14-15-25(24)34-31(30)39/h5-15,18,27H,3-4,16-17,19H2,1-2H3,(H,34,39)
SMILES Code
O=C1NC2=C(C=C(Br)C=C2)C(C3=CC=CC=C3)=C1C4=NN(C(CCN(CC)CC)=O)C(C5=CC=C(Br)C=C5)C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Human cancers often contain genetic alterations that disable G1/S checkpoint control and loss of this checkpoint is thought to critically contribute to cancer generation by permitting inappropriate proliferation and distorting fate-driven cell cycle exit. The identification of cell permeable small molecules that activate the G1/S checkpoint may therefore represent a broadly applicable and clinically effective strategy for the treatment of cancer
Preparing Stock Solutions
The following data is based on the
product
molecular weight
650.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW,
Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L,
Blagg J, Workman P, Garrett MD, Mittnacht S. Mechanism-based screen for G1/S
checkpoint activators identifies a selective activator of EIF2AK3/PERK
signalling. PLoS One. 2012;7(1):e28568. doi: 10.1371/journal.pone.0028568. PubMed
PMID: 22253692; PubMed Central PMCID: PMC3257223.
2: Bruch J, Xu H, Rösler TW, De Andrade A, Kuhn PH, Lichtenthaler SF, Arzberger
T, Winklhofer KF, Müller U, Höglinger GU. PERK activation mitigates tau pathology
in vitro and in vivo. EMBO Mol Med. 2017 Feb 1. pii: e201606664. doi:
10.15252/emmm.201606664. [Epub ahead of print] PubMed PMID: 28148553.
